E. Weber

1.7k total citations
83 papers, 1.1k citations indexed

About

E. Weber is a scholar working on Pharmacology, Pharmacology and Surgery. According to data from OpenAlex, E. Weber has authored 83 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pharmacology, 13 papers in Pharmacology and 11 papers in Surgery. Recurrent topics in E. Weber's work include Pharmacogenetics and Drug Metabolism (11 papers), Heparin-Induced Thrombocytopenia and Thrombosis (6 papers) and Pharmaceutical studies and practices (5 papers). E. Weber is often cited by papers focused on Pharmacogenetics and Drug Metabolism (11 papers), Heparin-Induced Thrombocytopenia and Thrombosis (6 papers) and Pharmaceutical studies and practices (5 papers). E. Weber collaborates with scholars based in Germany, United States and Switzerland. E. Weber's co-authors include Wolfgang Kruse, Ursula Gundert‐Remy, J. X. de Vries, I. Walter‐Sack, E. Walter, W. Eggert‐Kruse, B. Runnebaum, P. Georgi, B. Bubeck and Wolfgang Brandau and has published in prestigious journals such as Pain, Biochemical Pharmacology and Journal of Antimicrobial Chemotherapy.

In The Last Decade

E. Weber

80 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
E. Weber Germany 17 182 178 165 152 146 83 1.1k
Robert A. Hamilton United States 22 167 0.9× 165 0.9× 194 1.2× 102 0.7× 134 0.9× 79 1.8k
B.‐E. Wiholm Sweden 23 154 0.8× 233 1.3× 104 0.6× 76 0.5× 38 0.3× 35 1.7k
CF George United Kingdom 17 314 1.7× 258 1.4× 120 0.7× 42 0.3× 70 0.5× 28 1.2k
Paul A. Mitenko Canada 8 153 0.8× 375 2.1× 102 0.6× 285 1.9× 56 0.4× 12 1.2k
Odd Brørs Norway 21 123 0.7× 216 1.2× 210 1.3× 64 0.4× 40 0.3× 64 1.4k
Donald Perrier United States 23 304 1.7× 341 1.9× 147 0.9× 92 0.6× 29 0.2× 53 1.6k
Hans Liedholm Sweden 20 68 0.4× 196 1.1× 326 2.0× 63 0.4× 73 0.5× 47 911
Gillian M. Shenfield Australia 28 380 2.1× 322 1.8× 279 1.7× 329 2.2× 81 0.6× 114 2.3k
Klaus Mörike Germany 22 508 2.8× 241 1.4× 239 1.4× 104 0.7× 69 0.5× 65 1.6k
P. K. M. Lunde Norway 24 146 0.8× 326 1.8× 142 0.9× 146 1.0× 16 0.1× 52 1.3k

Countries citing papers authored by E. Weber

Since Specialization
Citations

This map shows the geographic impact of E. Weber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Weber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Weber more than expected).

Fields of papers citing papers by E. Weber

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Weber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Weber. The network helps show where E. Weber may publish in the future.

Co-authorship network of co-authors of E. Weber

This figure shows the co-authorship network connecting the top 25 collaborators of E. Weber. A scholar is included among the top collaborators of E. Weber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Weber. E. Weber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bubeck, B., Wolfgang Brandau, E. Weber, et al.. (2015). Renal Function Studies Using 99mTc-MAG3: Pharmacokinetics and Slope Clearance Determination. Contributions to nephrology. 79. 72–73. 3 indexed citations
2.
Weber, E. & Julian Donckier. (1994). [Cholestatic Jaundice Associated With Ticlopidine - a New Case]. Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)). 49(6). 309–310. 1 indexed citations
3.
Andrássy, K., et al.. (1994). Neutralization of the anticoagulant activity of low molecular weight heparin LU 47311 (Clivarin®) in man by protamine chloride. Thrombosis Research. 73(2). 85–93. 4 indexed citations
4.
Kruse, Wolfgang, et al.. (1993). Actual versus prescribed timing of lovastatin doses assessed by electronic compliance monitoring. European Journal of Clinical Pharmacology. 45(3). 211–215. 27 indexed citations
5.
Kruse, Wolfgang, et al.. (1993). Compliance and adverse drug reactions: a prospective study with ethinylestradiol using continuous compliance monitoring. Journal of Molecular Medicine. 71(6). 483–7. 12 indexed citations
6.
Walter‐Sack, I., et al.. (1993). Bioequivalence of allopurinol preparations: to be assessed by the parent drug or the active metabolite?. Journal of Molecular Medicine. 71(3). 240–6. 18 indexed citations
7.
Siebels, Michael, K. Andrássy, P. Vecsei, et al.. (1992). Dose dependent suppression of mineralocorticoid metabolism by different heparin fractions. Thrombosis Research. 66(5). 467–473. 21 indexed citations
8.
Kruse, Wolfgang, et al.. (1991). Dosage frequency and drug-compliance behaviour ? a comparative study on compliance with a medication to be taken twice or four times daily. European Journal of Clinical Pharmacology. 41(6). 589–592. 67 indexed citations
9.
Walter‐Sack, I., et al.. (1990). Variation of benzbromarone elimination in man — a population study. European Journal of Clinical Pharmacology. 39(2). 173–176. 12 indexed citations
10.
Kruse, Wolfgang, et al.. (1990). Compliance with Short-Term High-Dose Ethinyl Oestradiol in Young Patients with Primary Infertility. Birkhäuser Basel eBooks. 29. 105–115. 9 indexed citations
11.
Walter‐Sack, I., et al.. (1990). Rapid and slow benzbromarone elimination phenotypes in man: benzbromarone and metabolite profiles. European Journal of Clinical Pharmacology. 39(6). 577–581. 18 indexed citations
12.
Vries, J. X. de, et al.. (1989). The isolation, identification and structure of a new hydroxylated metabolite of benzbromarone in man. Xenobiotica. 19(12). 1461–1470. 13 indexed citations
13.
Vries, J. X. de, R. Raedsch, Uwe Völker, I. Walter‐Sack, & E. Weber. (1988). Biliary excretion of phenprocoumon and metabolites. European Journal of Clinical Pharmacology. 35(4). 433–436. 12 indexed citations
14.
Forster, Clemens, Fernand Anton, Peter W. Reeh, E. Weber, & Hermann O. Handwerker. (1988). Measurement of the analgesic effects of aspirin with a new experimental algesimetric procedure. Pain. 32(2). 215–222. 37 indexed citations
15.
Walter‐Sack, I., Michel Eichelbaum, J. X. de Vries, & E. Weber. (1988). Benzbromarone biotransformation is not related to polymorphic oxidation of sparteine. Journal of Molecular Medicine. 66(21). 1097–1098. 7 indexed citations
16.
Andrássy, K., Klaus Mörike, J. Koderisch, & E. Weber. (1988). Human pharmacological studies of a defined low molecular weight heparin fraction (Fragminr) evidence for a simultaneous inhibition of factor Xa and IIa (thrombin). Thrombosis Research. 49(6). 601–611. 8 indexed citations
17.
Gundert‐Remy, Ursula, et al.. (1982). Altered hydroxylation rate of triamterene in patients with liver cirrhosis.. PubMed. 20(8). 353–7. 1 indexed citations
18.
Harenberg, Job, et al.. (1980). Is the diurnal increase of fibrinolytic activity influenced by alpha- or beta-adrenergic blockade ?. Annals of Hematology. 41(6). 455–458. 4 indexed citations
19.
Walter, E., et al.. (1979). Action And Interaction Of Sulfinpyrazone In Anticoagulated Patients. Thrombosis and Haemostasis. 5 indexed citations
20.
Weber, E., et al.. (1963). Die Methoden der Duraplastik. Acta Neurochirurgica. 11(1). 34–60. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert A. Hamilton Breakdown of academic impact, for papers by B.‐E. Wiholm Breakdown of academic impact, for papers by CF George Breakdown of academic impact, for papers by Paul A. Mitenko Breakdown of academic impact, for papers by Odd Brørs Breakdown of academic impact, for papers by Donald Perrier Breakdown of academic impact, for papers by Hans Liedholm Breakdown of academic impact, for papers by Gillian M. Shenfield Breakdown of academic impact, for papers by Klaus Mörike Breakdown of academic impact, for papers by P. K. M. Lunde
Rankless by CCL
2026